LIXTE Biotechnology Holdings has appointed Sidney Braun as Chief Executive Officer of its Liora Technologies Europe Ltd. subsidiary. Braun previously facilitated LIXTE's November 2025 acquisition of Liora's assets and brings more than 20 years of healthcare operational and strategic advisory experience to the role.
Braun will lead advancement of Liora's LiGHT System, an electronically controlled proton therapy platform designed to enhance tumor treatment. Management stated the appointment supports its strategy to scale the technology and pursue a recurring revenue model within the radiotherapy segment of cancer care.
LIXTE Biotechnology Holdings is a clinical-stage pharmaceutical and med-tech company advancing cancer treatments. The company has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data available at https://www.lixte.com, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.
LIXTE's lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology called activation lethality that is advancing a new treatment paradigm. The company's new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer.
The appointment of Braun to lead the European subsidiary represents a strategic move to accelerate development of proton therapy technology while leveraging LIXTE's broader cancer treatment portfolio. Proton therapy represents a growing segment of radiation oncology that offers more precise targeting of tumors while minimizing damage to surrounding healthy tissue.
For business and technology leaders in healthcare, this development highlights the convergence of pharmaceutical development and medical technology in cancer treatment. The move suggests LIXTE is positioning itself to capture value across multiple modalities of cancer care, from drug development to advanced radiotherapy systems.
The full press release is available at https://ibn.fm/9kbfE. Forward-looking statements in the announcement are subject to risks and uncertainties, including those detailed in the company's SEC filings. Full terms of use and disclaimers applicable to all content provided by IBN are available at http://IBN.fm/Disclaimer.
